by Peter Ciszewski | Oct 3, 2018
Greg Duncan, CEO of Celtaxsys discusses cystic fibrosis (CF) and the role of pulmonary exacerbations. Celtaxsys recently announced top line results of its Phase 2 EMPIRE-CF trial evaluating oral, once daily anti-inflammatory molecule, acebilustat, for the...
by Peter Ciszewski | Oct 1, 2018
The U.S. Food and Drug Administration approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who...
by Peter Ciszewski | Sep 26, 2018
Greg Duncan, President and Chief Executive Officer of Celtaxsys, discusses working with advoacy groups such as the Cystic Fibrosis Foundation, on their clinical trials.
by Peter Ciszewski | Sep 23, 2018
Heather A. Lau, MD, Director, Lysosomal Storage Disease Program at NYU Langone in New York City discusses the important role of advocacy groups in rare diseases. One of the unique aspects of rare disease research has been the growing role of patient advocacy...
by Peter Ciszewski | Sep 22, 2018
Cory MacDonald, Operations Manager, Choroideremia Research Foundation, discusses choroideremia, his advocacy organization, and the various clinical trials for this rare eye disorder. Choroideremia is a condition characterized by progressive vision loss that mainly...
